Drug profile

The FDA adverse-event record for Glucosamine + Methylsulphonylmethane + Perna Canaliculus + Manganese + Dimethylglycine

12 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Glucosamine + Methylsulphonylmethane + Perna Canaliculus + Manganese + Dimethylglycine. See the species affected, top reactions, and outcomes below.

12
adverse-event reports
8.3%
death-coded share
Dog
most-reported species
3
Emesis - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
1
Deaths Reported
8.3%
Death Rate

Active Ingredients

Glucosamine + Methylsulphonylmethane + Perna Canaliculus + Manganese + Dimethylglycine

Administration Routes

OralUnknown

Species Affected

Dog 10
Cat 2

Most Affected Breeds

Retriever - Labrador 2
Chihuahua 1
Lhasa Apso 1
Terrier - Yorkshire 1
Maltese 1
Maine Coon 1
Domestic Shorthair 1
Hound - Basset 1
Dog (other) 1
Shepherd Dog (unspecified) 1

Most Reported Reactions

Emesis 3
Lethargy (see also Central nervous system depression in 'Neurological') 3
Vomiting 3
Elevated alanine aminotransferase (ALT) 2
Emesis (multiple) 1
Cough 1
Lack of efficacy (flea) 1
Skin and/or appendage neoplasm NOS 1
Anorexia 1
Elevated serum alkaline phosphatase (SAP) 1
Hypokalaemia 1
Elevated total bilirubin 1

Outcome Breakdown

Recovered/Normal
6 (50.0%)
Outcome Unknown
2 (16.7%)
Ongoing
2 (16.7%)
Recovered with Sequela
1 (8.3%)
Euthanized
1 (8.3%)

Glucosamine + Methylsulphonylmethane + Perna Canaliculus + Manganese + Dimethylglycine Adverse Event Insights

12 reports name Glucosamine + Methylsulphonylmethane + Perna Canaliculus + Manganese + Dimethylglycine; 1 recorded a death outcome (8.3% of reported events, not a population-level mortality rate). Active ingredient: Glucosamine + Methylsulphonylmethane + Perna Canaliculus + Manganese + Dimethylglycine. Administration routes: Oral, Unknown.

By species: Dog (10 reports), Cat (2 reports). By breed: Retriever - Labrador (2), Chihuahua (1), Lhasa Apso (1).

Leading clinical signs: Emesis (3), Lethargy (see also Central nervous system depression in 'Neurological') (3), Vomiting (3), Elevated alanine aminotransferase (ALT) (2). Outcome, 12 coded reports: Recovered/Normal leads at 50.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.